UCB is a global pharmaceutical company that places the patient at the center of all its activities. UCB’s mission is to improve the quality of life of patients suffering from severe immunological and central nervous system disorders as well as respiratory system and allergy illnesses. This is achieved through the discovery, development and marketing of innovative products. While aspiring towards offering innovative new medicines, UCB continues to expand its therapeutic areas of interest to satisfy unmet medical needs.
UCB envisions becoming a leading biopharmaceutical company of the next generation via a comparatively higher ratio of investment in research and development per employee than any other company in all fields of business within Europe coupled with its commitment to strategic acquisitions and partnering.
UCB was established in 1928 as Union Chimique Belge by the Belgian businessman Emmanuel Janssen and is headquartered in Brussels, Belgium. In 2004 UCB acquired the leading European biotechnology company, Celltech, which strengthened UCB presence in the biopharmaceutical market. In 2006, the acquisition of Schwarz Pharma further enriched the UCB pipeline and product range and took UCB into new fields, notably Parkinson’s disease. Today, UCB has a market presence in more than 40 countries and over 8000 employees worldwide.
UCB A.E. entered the Greek market in 1980 with a focus on promoting its parent company products. Today UCB A.E. employs approximately 110 employees under the direction of Mr. Leonidas Issopoulos as General Manager. UCB A.E. is headquartered in Argyroupolis, Athens and has an office in Thessaloniki.
At UCB, in order to succeed in our mission, we are committed to the following core values:
- Passion for performance
- Embracing difference
Despite today’s challenges, sales in Greece successfully grew to 46.7 € million in 2009 while worldwide sales turnover surpassed 3 € billion.
UCB enjoys significant achievements today due to the unique management model that secures the preservation of UCB’s identity, its autonomy and its continuous growth:
- Global leader in epilepsy and allergy
- Very promising presence in the biotechnology field and specifically in the area of rheumatoid disorders
- Included amongst the largest pharmaceutical companies worldwide and consistently in the top 20 in its field in Greece
By carefully studying our track record and results in all areas, we aim at continuously improving our performance, while ensuring uncompromised integrity and utmost respect towards the patient.
63, Ag. Dimitriou str. 174 56 – Alimos, Athens
+30 (210) 9974 000
+30 (210) 9956499 – 9956899